{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:39:49Z","timestamp":1789767589152,"version":"4.0.1"},"reference-count":49,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Ocular adverse events following COVID\u201019 vaccination are well described; however, systematic analyses of non\u2010COVID antiviral vaccines remain limited. This review aimed to evaluate ocular complications associated with non\u2010COVID antiviral immunizations, including influenza, varicella\u2010zoster (VZV), human papillomavirus (HPV), and hepatitis B (HBV) vaccines. A systematic search (PROSPERO CRD4202450873) identified 122 patients (184 eyes) from 8,487 publications, including case reports, case series, and observational studies. Uveitis was the most common (92\/184 eyes; 50.0%, 95% CI 42.8%\u201357.2%), frequently following influenza vaccination (35\/122; 28.7%, 95% CI 20.7%\u201336.7%). Most patients (95\/122; 77.9%, 95% CI 70.5%\u201385.3%) required systemic corticosteroids, reflecting predominant inflammation. Ocular symptoms occurred within 30 days in 84.4% (103\/122)of cases, with peak onset at 7\u201330 days (62\/122; 50.8%, 95% CI 42.0%\u201359.6%). Despite appropriate treatment, 18 patients (20.0%, 95% CI 13.0%\u201329.4%) experienced persistent inflammation or required therapy beyond 1 month, categorized as \u201clong\u2010vax\u201d, defined as ocular symptoms persisting for \u2265\u20094 weeks after vaccination. Although rare, antiviral vaccine\u2013associated ocular complications may persist, posing a risk of long\u2010term visual morbidity and emphasizing the importance of clinician awareness, postvaccination surveillance, and counseling for patients receiving repeated or combined vaccine exposures.<\/jats:p>","DOI":"10.1002\/jmv.70747","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T11:40:37Z","timestamp":1764934837000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Systematic Review of Postvaccination Ocular Adverse Events: A Comprehensive Analysis of Published Reports"],"prefix":"10.1002","volume":"97","author":[{"given":"Yaru","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Science, Graduate School of Medical and Dental Sciences Institute of Science Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2460-5234","authenticated-orcid":false,"given":"Koju","family":"Kamoi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Science, Graduate School of Medical and Dental Sciences Institute of Science Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Science, Graduate School of Medical and Dental Sciences Institute of Science Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Science, Graduate School of Medical and Dental Sciences Institute of Science Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Science, Graduate School of Medical and Dental Sciences Institute of Science Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Ohno\u2010Matsui","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Science, Graduate School of Medical and Dental Sciences Institute of Science Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2021.04.001"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.12.971"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094755"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000959"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3928\/01913913-20160405-04"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2016.03.023"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0968-y"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002537"},{"issue":"9","key":"e_1_2_12_10_1","first-page":"1167","article-title":"Adverse Events Monitoring as a Routine Component of Vaccine Clinical Trials: Evidence From the WHO Vaccine Trial Registry","volume":"78","author":"Mayans M. V.","year":"2000","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_12_11_1","unstructured":"Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products. vol WHO Technical Report Series No. 850 Annex 3: 97\u2013137. The Use of Essential Drugs Sixth report of the WHO Expert Committee. (World Health Organization 1995)."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14713"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14387"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15166"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231221081"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/joph\/6507997"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231213777"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050546"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13090950"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70286"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15030616"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101626"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.03.050"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2018.09.005"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2018-104"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.012"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1406800"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2017.53.7.2667582"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000199"},{"key":"e_1_2_12_31_1","unstructured":"vaccines. Sf. Centers for Disease Control and Prevention. February 2 2024.https:\/\/www.cdc.gov\/flu\/prevent\/flushot.html."},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2008.05.002"},{"issue":"11","key":"e_1_2_12_33_1","first-page":"690","article-title":"Vaccination\u2010Induced Bilateral Optic Neuritis: Rare but Existing","volume":"14","author":"Pillar G.","year":"2012","journal-title":"Israel Medical Association Journal: IMAJ"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986708786848712"},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","unstructured":"R.Mills S.Tyring andJ.Lawless \u201cSafety Tolerability and Immunogenicity of Zoster Vaccine in Subjects With A History of Herpes Zoster (HZ) \u201d [Abstract no. G\u2010407 Plus Poster]. (2008): 25\u201328.","DOI":"10.1016\/j.vaccine.2010.04.003"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(99)00552-6"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.10.007"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1201"},{"key":"e_1_2_12_39_1","unstructured":"Administration FaD. Gardasil (human papillomavirus quadrivalent [types 6 11 16 18] vaccine recombinant): product information and supporting documents accessed April 19 2024 http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm094042.htm."},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n136"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12020036"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3026"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-020-00843-z"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200012000-00016"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/icb.0000000000000761"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.0380"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00479-7"},{"key":"e_1_2_12_48_1","unstructured":"C. A. S.Vaccine Immunology. Plotkin SA Vaccines 6th ed. (2013)."},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.11.036"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00089-7"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.70747","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.70747","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.70747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:10:32Z","timestamp":1771312232000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.70747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/jmv.70747"],"URL":"https:\/\/doi.org\/10.1002\/jmv.70747","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70747"}}